ClinicalTrials.gg
RecruitingNCT06490484Updated Jul 8, 2024

Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin

A Phase 2 interventional study of HSK16149 20mg BID and Pregabalin 150mg BID in Diabetic Peripheral Neuropathic Pain, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-08.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies testing pregabalin in Neuralgia — 4 open to participants now, 4 under way, 1 of them phase 3. Pregabalin · Neuralgia.

Planned enrollment
28th of 50
90 · median 109
Started
2024
with 1 other
Phase 2
6 of 50
1 open now
Registered
48th of 50
by date

Among the 50 studies testing pregabalin in Neuralgia, this one is the 28th largest by planned enrollment, is one of 2 that started in 2024, is one of 6 in phase 2, and was the 48th registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

4 of the 50 studies testing pregabalin in Neuralgia are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing pregabalin in Neuralgia, or all of them as a file.
02

Study summary

Investigate the efficacy and safety of HSK16149 capsule in Chinese patients with Diabetic Peripheral Neuropathic Pain (DPNP) who had an inadequate response to Pregabalin, following 4 weeks treatment in comparison to Pregabalin

03

Conditions studied

  • Diabetic Peripheral Neuropathic Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed ;
  2. Males or females aged 18-75 years of age inclusive;
  3. Diagnosis of diabetic peripheral neuropathic pain (DPNP) and diabetic peripheral neuropathy (DPN) pain ≥ 6 months;
  4. ≤ 11.0% at screening and on a stable anti-diabetic medication regimen for at least 30 days prior to screening;
  5. Have a visual analog scale (VAS) pain value ≥60 mm in the past 24 h during screening;
  6. DPNP patients are currently receiving continuous treatment with pregabalin for more than 4 weeks who had an inadequate response.

Exclusion criteria

Exclusion Criteria:

  1. Peripheral neuropathy or pain unrelated to DPN that may confuse the assessment of DPNP.
  2. Skin conditions in the area affected by neurupathy that could alter sensation.
  3. Chronic systemic diseases that may affect subjects' participation in the study.
  4. Severe hematologic, hepatic or renal dysfunction, the subject will be excluded if:

    1. Neutrophils \< 1.5 × 10\^9/L, or \< 90 × 10\^9/L, or \< 100 g/L;
    2. /ALT > 2.5 × (ULN), or > 1.5 × ULN;
    3. Estimation of (eGFR) \< 60 mL/min / 1.73 m\^2;
    4. Creatine kinase > 2.0 × ULN.
  5. History of substance abuse or alcohol abuse.
  6. Acute complications of diabetes in the 6 months prior to screening.
  7. Any active infections at screening.
  8. or Ab positive, or Ab positive, or serum TP Ab positive.
  9. Inability or unwillingness to discontinue any other prohibited concomitant medications.
  10. History of allergic or medically significant adverse reaction to products or their , duloxetine or related compounds.
  11. History of suicidal behavior or attempted suicide.
  12. Pregnant or preparing for pregnancy or breastfeeding during the study period, or subjects were not willing to use reliable methods from the date of ICF signature until 28 days after the last trial drug administration, or planning to use progesterone contraceptives during this period.
  13. Participated in another clinical study within 30 days prior to screening.
  14. Other conditions of the subjects who are unlikely to comply with the protocol.
  15. The investigators determine that there are other conditions that are not suitable for participation in this study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    HSK16149 20mg BID

    Drug: HSK16149 20mg BID HSK16149 20mg, orally twice a day; treatment period: 4 weeks fixed dose.

    Drug: HSK16149 20mg BID

  • Experimental
    Pregabalin 150 BID

    Drug: Pregabalin 150mg BID Pregabalin 150mg, orally twice a day; treatment period: 1 week titration and 3 weeks fixed dose.

    Drug: Pregabalin 150mg BID

Interventions

  • DrugCrisugabalinStudies of CrisugabalinCrisugabalin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Drug: HSK16149 20mg BID HSK16149 20mg, orally twice a day; treatment period: 4 weeks fixed dose.

    Also known as: Crisugabalin

  • DrugPregabalinStudies of PregabalinPregabalin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Drug: Pregabalin 150mg BID Pregabalin 150mg, orally twice a day; treatment period: 1 week titration and 3 weeks fixed dose.

    Also known as: Pregabalin

06

What researchers measure

Primary outcomes

  1. Compare the change from baseline in Visual Analog Scale (VAS) between HSK16149 and Pregabalin at week 4.

    The VAS, in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain.

    Time frame: Baseline and week 4

Secondary outcomes

  1. Compare the change from baseline in Numeric Rating Scales (NRS) between HSK16149 and Pregabalin at week 4.

    The NRS, in which the participant rates pain on a 11-point numeric rating scale, where 0 = no pain and 10 = worst possible pain.

    Time frame: Baseline and week 4

  2. Compare the change from baseline in Visual Analog Scale (VAS) between HSK16149 and Pregabalin at treatment period.

    The VAS, in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain.

    Time frame: Baseline to week 4

  3. Compare the change from baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) betwwen HSK16149 and Pregabalin at week 4.

    Participants rate their pain in three parts of the questionnaire, which are combined into a single pain intensity score: Part 1 - fifteen descriptors of pain intensity, on a scale of 0 (none) to 3 (severe); Part 2 - the VAS, in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain; Part 3 - a present pain intensity index in which the participant rates present pain intensity on a scale of 0 (no pain) to 5 (most intense pain).

    Time frame: Baseline and week 4

  4. Compare the change from baseline in Daily Sleep Interference Score (DSIS) between HSK16149 and Pregabalin at week 4.

    The sleep interference scores on a scale of 0-10, where 0 = pain did not interfere with sleep to 10 = pain completely interfered with sleep. The weekly DSIS is based on participants daily sleep interference scores.

    Time frame: Baseline and week 4

  5. Compare the change from baseline in EuroQol-5-Domain-5-Level health questionnaire (EQ-5D-5L) between HSK16149 and Pregabalin at week 4.

    The EQ-5D-5L assessed quality of life based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant was asked to 'check the ONE box that best describes your health TODAY,' choosing from 5 options (no problems, slight problems, moderate problems, severe problems, extreme problems) provided under each dimension. The health state index value is a single value on a scale from 0 to 100 scores indicating better health: 0 = indicating worst health and 100 = best imaginable health.

    Time frame: Baseline and week 4

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Jul 2024, 2 months after the start.

Of 34 industry-sponsored phase 2 interventional studies under Neuralgia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 22. This study's planned 2 months is below that.

Counting every sponsor, half of 58 studies reached it within 22 months; a quarter within 11 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2024
First posted
Jul 8, 2024
StartActual
Apr 19, 2024
Primary completionEst.
Jul 12, 2024
CompletionEst.
Jul 14, 2024
Last update
Jul 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06490484
Responsible party
Sponsor
First posted
Jul 8, 2024
Start date
Apr 19, 2024
Primary completion
Jul 12, 2024 (estimated)
Completion
Jul 14, 2024 (estimated)
Last update
Jul 8, 2024

Study contacts

Fangqiong Li
Contact
lifangq@haisco.com
+8602867258840

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Crisugabalin · Pregabalin

Start the discussion